AGP Executive Report
Last update: an hour agoGerman Pharma: Merck KGaA raised its 2026 profit outlook for the third time, citing stronger performance and the Bio-Techne acquisition. Separately, the US FDA approved a Merck-licensed treatment for tenosynovial giant cell tumour. Medicine Costs: A study warns that higher drug prices in Germany could add $6.2 billion a year to US health insurers’ costs. Infectious Disease: Bird flu has re-emerged in German poultry and wild birds, including a positive wild goose in Brandenburg. Workforce Health: A report says Germans over 60 take about a month of sick leave each year, highlighting the health pressures facing an ageing workforce.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.